Findings revealed that FXYD5 promotes GBM progression via the PI3K/AKT/ACSL4 signaling axis and represents a potential therapeutic target for GBM.
Abstract
Glioblastoma (GBM) is the most malignant primary brain tumor, with limited therapeutic options. Dysregulation of FXYD5 has been reported in multiple malignancies, suggesting FXYD5 as a potential target for precision medicine. In the present study, FXYD5 expression and prognostic significance were analyzed using biological analysis on multiple databases and it was identified that FXYD5 was observably upregulated in GBM and inversely correlated with the prognosis of patients. Functional studies were investigated in LN229 and U251 GBM cell lines through FXYD5 knockdown and overexpression approaches, assessing proliferation (Cell Counting Kit-8), apoptosis (flow cytometry), migration/invasion (Transwell assays) and lipid metabolism (free fatty acids, triglycerides, cholesterol, Nile Red staining). Knockdown of FXYD5 suppressed GBM cell proliferation, migration and invasion, while increasing apoptosis, indicating that FXYD5 may serve as a therapeutic target for GBM. Mechanistic studies examined the PI3K/AKT/long-chain acyl-coenzyme A (CoA) synthase 4 4 (ACSL4) pathway via western blotting and rescue experiments, finding that FXYD5 activated the PI3K/AKT signaling pathway, leading to upregulation of ACSL4 and enhanced lipid metabolism. In vivo, a subcutaneous xenograft mouse model was used to evaluate whether PI3K/AKT inhibition could antagonize FXYD5 overexpression-induced tumor growth and PI3K/AKT inhibition reversed FXYD5 overexpression-induced tumor growth in the subcutaneous mouse model. These findings revealed that FXYD5 promotes GBM progression via the PI3K/AKT/ACSL4 signaling axis and represents a potential therapeutic target for GBM.
HSP90AA1 was significantly overexpressed in tumor tissues, and its high expression correlated with advanced International Federation of Gynecology and Obstetrics stage, lymphovascular space invasion, lymph node metastasis, and higher tumor grade.
L. Xue, Peng-Fei Wang, Chenlingzi Huang et al.· Cellular Signalling· 0 citations
Glioblastoma (GBM) is the most aggressive primary brain tumor, characterized by a poor prognosis and limited therapeutic options. In this study, we identify β3GnT2 (β-1,3-N-acetylglucosaminyltransferase 2) as a critical driver of GBM progression and a potential therapeutic target. β3GnT2 is significantly upregulated...
Peng-Fei Shi, Jie Xu, Dandan Zhang et al.· Cell Death & Disease· 0 citations
Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults, with a median survival of less than two years despite surgery, radiotherapy, and temozolomide. Its poor outcome reflects diffuse invasion, cellular heterogeneity, and the activation of overlapping pathways (PI3K/AKT/mTOR, Wnt/β-catenin,...
F. A. Jaber· Mini-Reviews in Medical Chem...· 0 citations
The GPX-4/GCLM axis, which balances redox, is highly expressed and crucial for GBM cell survival and aggressive biological behavior and may be a valuable adjunct to diagnosis, as demonstrated by RSL3, FIN56, and BSO.
M. Behera, S. Purkait, Amit Ghosh et al.· Neuro-Oncology· 0 citations
Pancreatic cancer (PC) is a highly lethal malignancy characterized by aggressive progression and limited treatment options. Current standard-of-care treatments only confer marginal survival benefits, highlighting an urgent unmet clinical need to identify novel actionable targets and mechanism-driven therapeutic regimen...
Hui-Deng Long, Hao Wang, Wei Xiang et al.· Biochimica et Biophysica Act...· 0 citations
It is demonstrated that MX1 promotes GC cell migration by suppressing ANXA2 ubiquitination and degradation, highlighting the critical role of the MX1-ANXA2 axis in GC progression.
Hang Yang, Huihan Ai, Zikun Wu et al.· Biochimica et Biophysica Act...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.